Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Kline

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|May 30, 2026
Outcomes and safety of CAR-T cell therapy in B-NHL patients with reduced left ventricular ejection fractionAlexandra E Rojek, Jia Guo, Justin Kline, et al.
Cell Reports|June 7, 2016
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid LeukemiaEmily Curran, Xiufen Chen, Leticia Corrales, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 24, 2019
Negligible Role for Deletion Mediated by cDC1 in CD8<sup>+</sup> T Cell ToleranceBrendan W MacNabb, Douglas E Kline, Annie R Albright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanomaJustin Kline, Ian E Brown, Yuan-Yuan Zha, et al.
Leukemia & Lymphoma|January 15, 2009
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemiaXavier Poiré, Andrew Artz, Richard A Larson, et al.
The Journal of Experimental Medicine|September 21, 2011
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cellsMercedes B Fuertes, Aalok K Kacha, Justin Kline, et al.
Leukemia & Lymphoma|May 26, 2010
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomasXavier Poiré, Justin Kline, David Grinblatt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2020
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell TransplantationAmy Y Wang, Justin Kline, Wendy Stock, et al.
Cancer|January 12, 2013
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomasJane E Churpek, Barbara Pro, Koen van Besien, et al.
Cancer Immunology Research|January 19, 2024
T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell AnalysesXiufen Chen, Jovian Yu, Girish Venkataraman, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|May 30, 2026
Outcomes and safety of CAR-T cell therapy in B-NHL patients with reduced left ventricular ejection fractionAlexandra E Rojek, Jia Guo, Justin Kline, et al.
Cell Reports|June 7, 2016
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid LeukemiaEmily Curran, Xiufen Chen, Leticia Corrales, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 24, 2019
Negligible Role for Deletion Mediated by cDC1 in CD8<sup>+</sup> T Cell ToleranceBrendan W MacNabb, Douglas E Kline, Annie R Albright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanomaJustin Kline, Ian E Brown, Yuan-Yuan Zha, et al.
Leukemia & Lymphoma|January 15, 2009
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemiaXavier Poiré, Andrew Artz, Richard A Larson, et al.
The Journal of Experimental Medicine|September 21, 2011
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cellsMercedes B Fuertes, Aalok K Kacha, Justin Kline, et al.
Leukemia & Lymphoma|May 26, 2010
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomasXavier Poiré, Justin Kline, David Grinblatt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2020
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell TransplantationAmy Y Wang, Justin Kline, Wendy Stock, et al.
Cancer|January 12, 2013
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomasJane E Churpek, Barbara Pro, Koen van Besien, et al.
Cancer Immunology Research|January 19, 2024
T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell AnalysesXiufen Chen, Jovian Yu, Girish Venkataraman, et al.
Pageof 10